Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan–Feb;64(1):9–29.
   PubMed Web of Science ®Google Scholar
• Toro JR, Travis LB, Wu HJ, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006 Dec 15;119(12):2922–2930.
   PubMed Web of Science ®Google Scholar
• Network NCC. Guidelines for Uterine Neoplasms Version 2. 2015.
   Google Scholar
• ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncology.2014 Sep;25Suppl 3:iii102–iii12.
   PubMed Web of Science ®Google Scholar
• Bogani G, Fuca G, Maltese G, et al. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol. 2016 Nov;143(2):443–447.
   PubMed Web of Science ®Google Scholar
• Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer (Oxford, England: 1990). 2008 Apr;44(6):808–818.
   PubMed Web of Science ®Google Scholar
• Gupta AA, Yao X, Verma S, et al. Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline. Current Oncol (Toronto, Ont). 2013 Oct;20(5):e448–e454.
   PubMed Web of Science ®Google Scholar
• Sanfilippo R, Grosso F, Jones RL, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011 Dec;123(3):553–556.
   PubMed Web of Science ®Google Scholar
• Pautier P, Floquet A, Chevreau C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015 Apr;16(4):457–464.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539–547.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma group (EORTC study 62043). J Clinical Oncol. 2009 Jul 1;27(19):3126–3132.
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2012 May 19;379(9829):1879–1886.
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007 Jul;6(7):2012–2021.
   PubMed Web of Science ®Google Scholar
• Boudou-Rouquette P, Tlemsani C, Blanchet B, et al. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1433–1444.
   PubMed Web of Science ®Google Scholar
• van Geel RM, Beijnen JH, Schellens JH Concise drug review: pazopanib and axitinib. Oncologist. 2012;17(8):1081–1089.
   PubMed Web of Science ®Google Scholar
• Keisner SV, Shah SR Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 05;71(4):443–454.
   PubMed Web of Science ®Google Scholar
• Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014 Nov 11;111(10):1909–1916.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clinical Cancer Res. 2009 Jun 15;15(12):4220–4227.
   PubMed Web of Science ®Google Scholar
• Deng Y, Sychterz C, Suttle AB, et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443–453.
   PubMed Web of Science ®Google Scholar
• Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Dec;88(6):818–823.
   PubMed Web of Science ®Google Scholar
• Heath EI, Forman K, Malburg L, et al. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs. 2012 Aug;30(4):1566–1574.
   PubMed Web of Science ®Google Scholar
• Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clinical Pharmacokinetics. 2011 Sep;50(9):551–603.
   PubMed Web of Science ®Google Scholar
• Minocha M, Khurana V, Qin B, et al. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Int J Pharm. 2012 Oct 15; 436 (1–2): 127–134.
   PubMed Web of Science ®Google Scholar
• Gril B, Palmieri D, Qian Y, et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLos One. 2011;6(10):e25625.
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphism. Br J Cancer. 2010 Apr 27;102(9):1371–1377.
   PubMed Web of Science ®Google Scholar
• Xu CF, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. JHepatol. 2011 Jun;54(6):1237–1243.
   PubMed Web of Science ®Google Scholar
• Kasper B, Sleijfer S, Litiere S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 2014 Mar;25(3):719–724.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim HS, Lee SJ, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer. 2015 Mar 19;15:154.
   Web of Science ®Google Scholar
• Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016 May 01;122(9):1408–1416.
   PubMed Web of Science ®Google Scholar
• Benson C, Ray-Coquard I, Sleijfer S, et al. Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecol Oncol. 2016 Jul;142(1):89–94.
   PubMed Web of Science ®Google Scholar
• Kapadia S, Hapani S, Choueiri TK, et al. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 2013 Aug;52(6):1202–1212.
   PubMed Web of Science ®Google Scholar
• Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1635–1643.
   PubMed Web of Science ®Google Scholar
• Commissioner Oot. Safety Information - Votrient (Pazopanib) Tablets. UK:GlaxoSmithKline; 2017.
   Google Scholar
• Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652–659.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Boers-Sonderen MJ, van der Graaf WT, et al. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer. 2014 Feb 18;110(4):888–893.
   PubMed Web of Science ®Google Scholar
• Imbs DC, Dieras V, Bachelot T, et al. Pharmacokinetic interaction between pazopanib and cisplatin regimen. Cancer Chemother Pharmacol. 2016 Feb;77(2):385–392.
   PubMed Web of Science ®Google Scholar
• Imbs DC, Negrier S, Cassier P, et al. Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol. 2014 Jun;73(6):1189–1196.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014 Apr;15(4):415–423.
   PubMed Web of Science ®Google Scholar
• Seddon B, Scurr M, Jones RL, et al. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res. 2015;5:13.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clinical Oncol. 2002 Jun 15;20(12):2824–2831.
   PubMed Web of Science ®Google Scholar
• Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clinical Oncol. 2007 Jul 01;25(19):2755–2763.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol. 2012 Jan;124(1):48–52.
   PubMed Web of Science ®Google Scholar
• Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clinical Oncol. 2011 Jun 20;29(18):2528–2533.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Miller A, O’Malley DM, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 1;33(10):1180–1185.
   PubMed Web of Science ®Google Scholar